BioSpace News Archive

Allakos Inc. today announced a restructuring to reduce costs and to focus on AK006 clinical development and additional preclinical programs. As a result, the Company’s cash runway is expected to extend into mid-2026.

Ecovyst Inc. today announced that Kara L. Thornton has been appointed Vice President and Chief Human Resources Officer.

In a first-in-human study, researchers at Orlucent, Inc. have demonstrated the viability of a novel handheld point-of-care molecular Skin Fluorescence Imaging (mSFI) System to noninvasively identify and clinically assess the presence of biological tissue remodeling activity associated with the development of melanoma in adults.

On September 5, 2023, restor3d, Inc. finalized its previously announced acquisition of Conformis, Inc. With this merger complete, there is tremendous opportunity to deliver clinically differentiated and cost-effective solutions across the orthopaedic landscape.

60 Degrees Pharmaceuticals, Inc. announced that on January 10, 2024 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC stating the Company has regained compliance with the minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.

Integer Holdings Corporation, a leading medical device outsource manufacturer, will join medtech leaders and innovators around the world in exhibiting at the North American Neuromodulation Society Annual Meeting at Caesars Palace in Las Vegas from Jan. 18 – 21, 2024.

Panbela Therapeutics, Inc. announced that it will implement the previously announced and stockholder approved 1-for-20 reverse split of its common stock.

Instil Bio, Inc., a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, announced a strategic update.

NightHawk Biosciences, an integrated contract development and manufacturing organization, announced its Scorpius BioManufacturing subsidiary has been awarded a project to support a preclinical program for a U.S. based biotech company.

Milestone Scientific Inc. provided the following letter to shareholders from the Company’s CEO, Arjan Haverhals, including updates regarding commercialization of the CompuFlo® technology and initial reimbursements of CompuFlo by commercial payors and Medicare.